We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The 2-year incidence of myopia was 28.4% in the 0.05% ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Children with myopia using 0.05% atropine eye drops had less myopia progression and/or less axial elongation compared with those using placebo or 0.01% atropine, though they had higher rates of ...

A study conducted at Vanderbilt University Medical Center and 11 other hospitals and practices across the United States shows that use of low-dose atropine eyedrops, commonly used in a higher dose to ...

In a cohort of over 1.2 million Taiwanese children followed up for at least 5 years, those with myopia had a higher risk for ocular problems than those without the condition. However, among children ...

A new clinical trial has found that a common eye drop is a safe and effective way to slow the progression of nearsightedness in children. The finding may provide an easier way of treating the ...

Share on Pinterest Experts say the incidence of nearsightedness in children is rising. Catherine Falls Commercial/Getty Images Experts say that developing nearsightedness as a child might be an ...

Over 24 months, kids using the once-nightly drops and those using placebo saw mean changes in spherical equivalent refractive error (SER) of -0.82 D (95% CI -0.96 to ...

Credit: Getty Images. A PDUFA target date of January 31, 2024 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for NVK002 ...

Iveena Delivery Systems Inc. has been awarded a $2 million phase II Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) to advance the development of novel topical ...

Here's what to look for (and steer clear of!) when choosing eye drops.